Identification of novel diagnostic biomarkers for thyroid carcinoma

Xiliang Wang; Qing Zhang; Zhiming Cai; Yifan Dai; Lisha Mou

doi:10.18632/oncotarget.22873

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Identification of novel diagnostic biomarkers for thyroid carcinoma

Xiliang Wang, Qing Zhang, Zhiming Cai, Yifan Dai and Lisha Mou _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:111551-111566. https://doi.org/10.18632/oncotarget.22873

Metrics: PDF 1605 views | HTML 1769 views | ?

Abstract

Xiliang Wang1,2, Qing Zhang1, Zhiming Cai1, Yifan Dai3 and Lisha Mou1

1Shenzhen Xenotransplantation Medical Engineering Research and Development Center, Institute of Translational Medicine, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China

2Department of Biochemistry in Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 510080, China

3Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing 210029, China

Correspondence to:

Lisha Mou, email: [email protected]

Keywords: thyroid carcinoma; bioinformatics; dysregulation network; biomarker

Received: June 27, 2017 Accepted: November 19, 2017 Published: December 04, 2017

ABSTRACT

Thyroid carcinoma (THCA) is the most universal endocrine malignancy worldwide. Unfortunately, a limited number of large-scale analyses have been performed to identify biomarkers for THCA. Here, we conducted a meta-analysis using 505 THCA patients and 59 normal controls from The Cancer Genome Atlas. After identifying differentially expressed long non-coding RNA (lncRNA) and protein coding genes (PCG), we found vast difference in various lncRNA-PCG co-expressed pairs in THCA. A dysregulation network with scale-free topology was constructed. Four molecules (LA16c-380H5.2, RP11-203J24.8, MLF1 and SDC4) could potentially serve as diagnostic biomarkers of THCA with high sensitivity and specificity. We further represent a diagnostic panel with expression cutoff values. Our results demonstrate the potential application of those four molecules as novel independent biomarkers for THCA diagnosis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22873

Publication Alerts

Research Papers:

Identification of novel diagnostic biomarkers for thyroid carcinoma

Abstract